Loading…
← CockpitCompetitor Analysis › 301507.SZ Hangzhou Minsheng Healthcare Co., Ltd. Class AOpen in the cockpit ↗

Hangzhou Minsheng Healthcare Co., Ltd. Class A301507.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Other
Momentum neutral 49
Mkt cap
$583M
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$7.54M
20-day average traded
Fwd P/E
45.4×
forward earnings
ROIC−WACC
-0.6 pp
WACC 7.9%
Hurdle
+7 pp
Req g minus delivered
Next earnings
162 days
29 Apr 2027
Close · CNYCN¥11.02
1D-1.8%
1W-5.7%
1M-12.9%
3M-15.6%
6M-23.5%
YTD-28.3%
1Y-25.5%
ATR %3.9%
52w lowhigh42.8% off high

What Hangzhou Minsheng Healthcare does

Employees: 727

Hangzhou Minsheng Healthcare at a glance

Size Hangzhou Minsheng Healthcare (301507.SZ) is a China Health Care company (Pharmaceuticals: Other) with a market value of $583M, the 3321st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥11.02 on 18 Nov 2026.

Performance Over six months the shares fell 23.5%, against -21.0% for the median peer and -20.0% for the China market (cap-weighted) — 9th lowest of 21 in its peer set.

Growth Revenue grew 21.3% over the last twelve months (peer median -1.8%); the operating margin is 10.8% (peer median 7.2%).

Valuation It trades at 45.4× forward earnings against a peer median of 21.4× (4th most expensive of 10).

Price implies For today's price to make sense, revenue must grow about 19% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +7 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 0.6 points below its cost of capital (7.9% WACC).

Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026Peer median 80301507.SZ 78
Six months, rebased to 100: Hangzhou Minsheng Healthcare against the median of its 20 peers (local-currency closes).

Hangzhou Minsheng Healthcare financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥903MCN¥779MCN¥636MCN¥578MCN¥543M
Revenue growth—+22%+10%+6%—
Gross profitCN¥496MCN¥384MCN¥344MCN¥349MCN¥318M
EBITDAn/aCN¥117MCN¥98.4MCN¥107MCN¥108M
Net incomeCN¥88.6MCN¥119MCN¥91.8MCN¥85.6MCN¥79.0M
Free cash flowCN¥42.6M-CN¥6.28MCN¥23.7MCN¥72.1MCN¥68.4M
Capital expenditureCN¥182MCN¥196MCN¥94.9MCN¥36.1MCN¥26.9M
Total debtCN¥64.8MCN¥33.6MCN¥19.5MCN¥10.6MCN¥11.8M

Quarterly statements and history in the cockpit →

Hangzhou Minsheng Healthcare competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%-20%0%300261AVBP077500264400241230015800256230003960366960048831745028776032620460PHNBOI002219APN301507.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Hangzhou Minsheng Healthcare is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%0×200×400×30026130079128776032620460PHNBOI002219APN301507.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Hangzhou Minsheng Healthcare is the large dot.

Capital: growth delivered against growth the price implies

0%+10%+20%+30%+40%0%20%40%002644002412002562300039600488300791002826603262PHNBOIAPN301507.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Hangzhou Minsheng Healthcare is the large dot.

Hangzhou Minsheng Healthcare competitors and peer comparison

How Hangzhou Minsheng Healthcare compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Hangzhou Minsheng Healthcare against its 20 peers (data as of 18 Nov 2026)
Measure301507.SZPeer medianRank in peer set
1-month return-12.9%-9.8%5th lowest of 21
6-month return-23.5%-21.0%9th lowest of 21
Distance from 52-week high-42.8%-43.4%11th highest of 21
Revenue growth (TTM)+21.3%-1.8%3rd highest of 20
Operating margin10.8%7.2%10th highest of 21
Forward P/E45.4×21.4×4th most expensive of 10
Growth the price implies (Req g, 7 yrs)19.1%4.0%3rd most demanding of 12
Growth delivered (Del g)+12.1%+7.0%6th highest of 12
Hurdle (Req g minus delivered)+7.0 pp-1.4 pp3rd most demanding of 12
ROIC minus cost of capital-0.6 pp-0.1 pp9th lowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Hangzhou Minsheng Healthcare 301507.SZChina$583M-23%+21%11%45.4×19.1%+12.1%
ABA Chemicals 300261.SZChina$592M-26%-16%-23%405.0×n/an/a
ArriVent BioPharma AVBPUnited States$564M-60%n/a-3,620%n/an/an/a
CK Life Sciences International (Holdings) 0775.HKHong Kong$613M-30%0%0%n/an/an/a
Lanzhou Foci Pharmaceutical 002644.SZChina$548M-9%+6%6%n/a15.4%+6.5%
Hunan Hansen Pharmaceutical 002412.SZChina$532M-2%-4%21%n/a1.4%+7.0%
Shanxi Zhendong Pharmaceutical 300158.SZChina$641M-22%-28%-25%n/an/an/a
Brother Enterprises 002562.SZChina$668M-33%+8%4%n/a4.0%+13.5%
Shanghai Kaibao Pharmaceutical 300039.SZChina$703M-20%-14%22%n/a0.4%+4.8%
Lionco Pharmaceutical 603669.SSChina$474M+4%-6%-17%n/an/an/a
Tianjin Tianyao Pharmaceuticals 600488.SSChina$718M-36%-12%3%n/a2.1%-1.3%
Myung in Pharm 317450.KSSouth Korea$466M-20%+7%35%n/an/an/a
Sirio Pharma 300791.SZChina$759M-6%-9%1%16.2×14.1%+15.6%
China Shineway Pharmaceutical 2877.HKHong Kong$760M-8%-18%25%7.6×n/an/a
Tibet Aim Pharm 002826.SZChina$407M-22%+13%14%n/a0.4%+1.0%
TSI 603262.SSChina$842M-46%+3%14%47.7×24.3%+13.4%
Sihuan Pharmaceutical 0460.HKHong Kong$856M-34%+30%15%8.7×n/an/a
PharmaNutra PHN.MIItaly$922M+2%+17%22%33.5×4.7%+18.5%
Boiron BOI.PAFrance$367M-31%-2%5%9.3×-0.8%-0.5%
New Journey Health Technology Group Co., Ltd.Class A 002219.SZChina$942M-18%-14%8%182.0×n/an/a
Applied Nutrition APN.LUnited Kingdom$986M+31%+51%25%21.4×24.6%+38.5%

Questions

Which companies are Hangzhou Minsheng Healthcare's closest peers?
The cockpit's peer set: ABA Chemicals (300261.SZ), ArriVent BioPharma (AVBP), CK Life Sciences International (Holdings) (0775.HK), Lanzhou Foci Pharmaceutical (002644.SZ), Hunan Hansen Pharmaceutical (002412.SZ), Shanxi Zhendong Pharmaceutical (300158.SZ), Brother Enterprises (002562.SZ), Shanghai Kaibao Pharmaceutical (300039.SZ).
Is Hangzhou Minsheng Healthcare expensive compared with its peers?
On forward p/e it trades at 45.4× against a peer median of 21.4×, 4th most expensive of 10 in its peer set. For today's price to make sense, revenue must grow about 19% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +7 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Hangzhou Minsheng Healthcare stock performed?
Over six months to 18 Nov 2026 the shares returned -23.5% against -21.0% for the median peer; over one year -25.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.